Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Sexual Function & Reproductive

PT-141

Bremelanotide

Also known as: Vyleesi Bremelanotide

Evidence: Strong clinical Disclaimer: Standard FDA-approved

Mechanism & research context

Melanocortin (MC4R) agonist acting centrally. FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

FDA-approved indication: Hypoactive sexual desire disorder (HSDD) in premenopausal women (Vyleesi).

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

5 records
  • Live search Live search

    Live ClinicalTrials.gov search: PT-141

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT00425256 PHASE2 COMPLETED

    Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

    Condition: Sexual Arousal Disorder

    Sponsor: Palatin Technologies, Inc

    Open on ClinicalTrials.gov ↗
  • NCT01382719 PHASE2 COMPLETED

    A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)

    Condition: Female Sexual Arousal Disorder; Hypoactive Sexual Desire Disorder

    Sponsor: Palatin Technologies, Inc

    Open on ClinicalTrials.gov ↗
  • NCT02333071 PHASE3 COMPLETED

    Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

    Condition: Hypoactive Sexual Desire Disorder

    Sponsor: Palatin Technologies, Inc

    Open on ClinicalTrials.gov ↗
  • NCT02338960 PHASE3 COMPLETED

    Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

    Condition: Hypoactive Sexual Desire Disorder

    Sponsor: Palatin Technologies, Inc

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for PT-141 yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of PT-141, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for PT-141. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.